MNTA Share Price

Open 14.00 Change Price %
High 14.38 1 Day 0.35 2.50
Low 13.90 1 Week 1.25 9.54
Close 14.35 1 Month 0.90 6.69
Volume 706747 1 Year 4.84 50.89
52 Week High 19.90
52 Week Low 8.82
MNTA Important Levels
Resistance 2 14.79
Resistance 1 14.61
Pivot 14.21
Support 1 14.09
Support 2 13.91
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
STRT 32.15 30.16%
WRES 0.09 28.57%
TBBK 6.45 27.47%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
EHTH 14.18 20.78%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
ROSE 10.35 -48.20%
ROSE 10.35 -48.20%
DVOX 0.05 -44.44%
More..

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

MNTA Technical Analysis 1.5
As on 28th Apr 2017 MNTA Share Price closed @ 14.35 and we RECOMMEND Buy for LONG-TERM with Stoploss of 13.26 & Sell for SHORT-TERM with Stoploss of 14.59 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNTA Target for May
1st Target up-side 15.01
2nd Target up-side 16.18
3rd Target up-side 17.34
1st Target down-side 11.69
2nd Target down-side 10.52
3rd Target down-side 9.36
MNTA Other Details
Segment EQ
Market Capital 681705792.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.momentapharma.com
MNTA Address
MNTA
675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617-491-9700
Fax: 617-621-0431
MNTA Latest News
Interactive Technical Analysis Chart Momenta Pharmaceuticals, Inc. ( MNTA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Momenta Pharmaceuticals, Inc.
MNTA Business Profile
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.